Massachusetts General Hospital Cancer Center

https://www.massgeneral.org/cancer-center

 

Videos
09:39

Massachusetts General Hospital Cancer Center

Overcoming Clinical Barriers: Integrating Liposomal Irinotecan Into 1L Pancreatic Cancer Treatment

FEATURING Priya Pathak
  • 1 view
  • December 20, 2024
08:10

2024 ASH Annual Meeting Insights Hub

ASH 2024 Insights: Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in 1L CLL - 5yr Follow up, Retreatment, and MRD Kinetics

FEATURING Jake Soumerai
  • 59 views
  • December 20, 2024
09:51

2024 ASH Annual Meeting Insights Hub

ASH 2024 Insights: Sonrotoclax + Zanubrutinib in 1L CLL - Results From the BGB-11417-101 Study

FEATURING Jake Soumerai
  • 15 views
  • December 20, 2024
05:36

2024 ASH Annual Meeting Insights Hub

ASH 2024 Insights: Ziftomenib + Ven/Aza in R/R NPM1mut or KMT2A-r AML - Interim KOMET-007 Results

FEATURING Amir Fathi
  • 7 views
  • December 16, 2024
18:48

Massachusetts General Hospital Cancer Center

Proton-Based Radiation Therapy for Chordomas

FEATURING Fantine Giap
  • December 12, 2024
14:31

Massachusetts General Hospital Cancer Center

Pomalidomide for Epistaxis in Hereditary Hemorrhagic Telangiectasia: Results From the PATH-HHT Trial

FEATURING Hanny Al-Samkari
  • 54 views
  • November 21, 2024
26:55

Massachusetts General Hospital Cancer Center

Understanding ESR1 Mutations in HR+/HER2- mBC: Testing Methods, Patient Selection, Treatment Decision-Making

FEATURING Seth Wander
  • 318 views
  • August 2, 2024
  • 2
11:21

Massachusetts General Hospital Cancer Center

Uveal Melanoma for Community Oncologists

FEATURING Kamaneh Montazeri
  • 114 views
  • January 18, 2024
14:06

Insights from 2023 Society for Melanoma Research Annual Meeting

2023 SMR Congress Insights: "Time-to-Event Machine Learning Prediction of Metastatic Recurrence From Early Stage Melanoma"

FEATURING Yevgeniy Semenov
  • 60 views
  • November 24, 2023
18:31

SOHO 2023 Eleventh Annual Meeting

SOHO 2023: CAR/BsAb Toxicity in MM - Prevention, Treatment, and Surveillance

FEATURING Noopur S. Raje
  • 161 views
  • October 12, 2023
  • 1
10:42

Insights from 2023 EHA® Annual Meeting

Updated Data for Ziftomenib in Adults With NPM1-Mutated R/R AML

FEATURING Amir Fathi
  • 242 views
  • August 8, 2023
06:25

Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Phase 1/2 TRIDENT-1 Trial - Intracranial and Systemic Efficacy of Repotrectinib in Advanced ROS1+ NSCLC & CNS Mets"

FEATURING Jessica Lin
  • 86 views
  • July 2, 2023
  • 1
16:49

Massachusetts General Hospital Cancer Center

ESR1 Mutations in HR+/HER2- mBC and Their Role in Treatment Outcomes

FEATURING Seth Wander
  • 251 views
  • May 12, 2023
  • 1
17:54

Massachusetts General Hospital Cancer Center

Genetic Heterogeneity in Brain Metastases and Implications for Clinical Trial Design

FEATURING Priscilla Brastianos
  • 15 views
  • April 3, 2023
09:52

Massachusetts General Hospital Cancer Center

Maintenance Therapy in AML: Protecting Remission, Extending Survival, and Preventing Early Relapse

FEATURING Andrew Brunner
  • 219 views
  • February 2, 2023
  • 3
08:20

Massachusetts General Hospital Cancer Center

ESMO 2021 Updates on 1L DKN-01 + Tislelizumab & Chemotherapy in Advanced GEA: DisTinGuish Trial

FEATURING Samuel Klempner
  • 110 views
  • October 13, 2021
12:08

Massachusetts General Hospital Cancer Center

Selpercatinib Efficacy & Safety in Patients With RET-Altered Thyroid Cancer: LIBRETTO-001 Update

FEATURING Lori Wirth
  • 43 views
  • August 26, 2021
10:05

i3 Health

Emerging Treatment Strategies for Advanced Cholangiocarcinoma: Molecular Pathogenesis, Novel Therapies, and AEs Management

FEATURING Lipika Goyal
  • 211 views
  • August 4, 2021
  • 2
50:37

Massachusetts General Hospital Cancer Center

Next Steps in FGFRi in Cholangiocarcinoma: FGFR Pathway & Current Landscape of Inhibitors, Drug Failure, and Pipeline of Next Generation of Trials

FEATURING Lipika Goyal
  • 238 views
  • August 4, 2021
  • 2
04:27

Massachusetts General Hospital Cancer Center

ASCO 2021 Highlights From GEOMETRY mono-1 Study on Advanced NSCLC: Capmatinib in METex14 or MET-Amplified Disease

FEATURING Rebecca Heist
  • 40 views
  • July 6, 2021
  • 1
16:46

Virtual West Oncology Conference

2021 Updates on mTNBC: Do Olaparib/Talazoparib Improve PFS Compared to Chemo? Is Atezo+Nab-Paclitaxel Beneficial for OS/PFS? Should We Use Sacituzumab Govitecan in R/R Disease?

FEATURING Neelima Vidula
  • 72 views
  • March 9, 2021
  • 1
18:15

GRACE

Targeted Therapy for EGFR+ NSCLC: What Are the Current Options Upon Acquired Resistance to Osimertinib?

FEATURING Zofia Piotrowska
  • 104 views
  • March 1, 2021
  • 1
10:33

GRACE

Targeted Therapy for EGFR+ NSCLC: How Do We Think About Acquired Resistance? How to Assess for Osimertinib Resistance?

FEATURING Zofia Piotrowska
  • 114 views
  • March 1, 2021
  • 1
31:44

Massachusetts General Hospital Cancer Center

Tumor Infiltrating Lymphocytes: What Is the Data That Supports the Predictive Power of Seeing CD8 Positive T-Cells in the Tumor?

FEATURING Keith Flaherty
  • 18 views
  • February 5, 2021
13:52

2020 ASCO Virtual Direct™ Highlights

Targeting Exon 20 Insertions in NSCLC: Anti-Tumor Activity With T-Dxd in HER2m Disease, Assessing Efficacy of Treatment Options in EGFRm Disease

FEATURING Ibiayi Dagogo-Jack
  • 327 views
  • January 28, 2021
  • 3
05:44

2020 Virtual ESMO Review

2020 ESMO Update on Targeted Therapy in NSCLC: Can We Safely Combine Amivantamab + Lazertinib in Advanced EGFR+ Disease?

FEATURING Ibiayi Dagogo-Jack
  • 29 views
  • November 25, 2020
07:33

2020 Virtual ESMO Review

2020 ESMO Update on Targeted Therapy in NSCLC: Does ADAURA Trial Suggest Clinically Meaningful Improvement in CNS DFS With Osimertinib? Does Heavily Pretreated KRAS G12C-Mutant NSCLC Respond to Sotorasib?

FEATURING Ibiayi Dagogo-Jack
  • 177 views
  • November 25, 2020
07:14

ecancer

2020 ESMO Update on ADCs in mTNBC: Is Sacituzumab Govitecan More Beneficial for OS & PFS Compared to Standard Chemotherapy?

FEATURING Aditya Bardia
  • 273 views
  • November 13, 2020
  • 1
13:34

2020 Virtual ESMO Review

2020 ESMO Update on Targeted Therapy in NSCLC: Can We Safely Combine Amivantamab + Lazertinib in Advanced EGFR+ NSCLC? Is There a Clinically Meaningful Improvement in CNS DFS With Osimertinib? Does Heavily Pretreated NSCLC Respond to Sotorasib?

FEATURING Ibiayi Dagogo-Jack
  • 28 views
  • November 11, 2020
26:39

Virtual Diversity in Cancer Care

Risk Factors in Lung Cancer: Which Risk Factor Is Predominant? How Important Is Screening?

FEATURING Ibiayi Dagogo-Jack
  • 157 views
  • November 11, 2020
  • 2